Changes in serum concentrations of tumor necrosis factor-α (TNF-α) and its soluble receptors (sTNF-R) p55 and p75 have been shown to be associated with various psychiatric treatments.
Introduction
In recent years, cytokines, which are messenger molecules of the immune system, have received increasing attention in psychiatric research (Borovcanin et al. 2012 , Borovcanin et al. 2013 , Maes et al. 2012 , Müller et al. 2015 as they can influence various types of brain cells and their connectivity, the production and metabolism of neurotransmitters, and neuroendocrine systems (Miller et al. 2013) . One cytokine that has been the subject of much scientific interest among researchers is tumor necrosis factor (TNF)-α (Berthold-Losleben & Himmerich 2008). It acts via two different receptors which can be cleaved from the surface of different types of cells and are measurable in the serum as soluble TNF-α receptors sTNF-R p55 and sTNF-R p75.
TNF-α is a glycoprotein hormone which was isolated as a soluble factor released by host cells that caused necrosis of a transplanted tumor (Carswell et al. 1975) . It is released by monocytes, macrophages and other white blood cells, the endothelium, fatty tissue and several other body tissues and is involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation.
TNF-α has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance and cancer (Ghezzi & Cerami 2005) .
Changes in the TNF-α system have been shown to be associated with a number of psychiatric disorders such as schizophrenia (Pandey et al. 2015 , Turhan et al. 2016 ) and depression Schmidt et al. 2014 ). However, in post-traumatic stress disorder (PTSD), results are inconsistent; some studies report increased production of TNF-α in have been shown to lead to changes in the TNF-α system, most often to an increase in plasma levels of TNF-α and its receptors. However, an increase of TNF-α production during therapy is not generally conceived as a favorable effect, as TNF-α is an inflammatory marker that has been shown to be associated with psychiatric disorders such as schizophrenia ( Schmidt et al. 2014) . Moreover, animal studies have shown that TNF-α production increases during stressful events such as social isolation (Krügel et al. 2014 ).
The effect of psychological therapies on TNF-α levels is less clear. Studies indicate that dynamic psychotherapy (Del Grande da Silva et al. 2016) and cognitive behavior therapy, but not narrative cognitive therapy (Moreira et al. 2015) , may lead to decreased TNF-α production in depressed patients. To our knowledge, the effect of psychotherapy for PTSD on serum levels of TNF-α or its receptors has never been reported. To investigate this, we measured these parameters in soldiers with combat-related PTSD before and after treatment. Cytokine measurement: After blood drawing at baseline and after treatment, serum probes were immediately centrifuged at 3000 rpm for 10 min. The supernatant was aliquoted and stored in non-absorbing polypropylene tubes of 300 μl. Probes were shock-frozen in liquid nitrogen and stored in freezers at -80 ºC until further measurement. TNF-α and its soluble All statistical tests were performed using SPSS 21. As this was a pilot study, we accepted an uncorrected p-value of p < .05 as an indicator of statistical significance.
Ethics: The study was approved by the local ethics committee (Ethikausschuss Charité, application number: EA1/270/11).
Results
Psychosocial group characteristics: Mean age of the whole study sample (including the inpatient and outpatient treatment groups) was 28.5 (±5.6) years, and the average body mass index (BMI) was 27.3 (±3.4) kg/m 2 . Age, BMI and PDS score are shown separately for each treatment group in Table 1 . At baseline, the whole sample showed a PDS score of 31.5 (±10.5) and after treatment a score of 28 Parameters of the TNF-α system: Table 1 also shows the serum concentrations of TNF-α and its soluble receptors sTNF-R p55 and sTNF-R p75 separately for both treatment groups.
Regarding the whole group, there was a significant increase over time with regard to TNF-α 
Discussion
Both treatment groups showed a significant decrease in PTSD symptoms after treatment as measured by the PDS score. In addition, whereas TNF-α concentrations increased, sTNF-R p55 and sTNF-R p75 levels decreased significantly over time in the whole study sample. To our knowledge, this is the first study investigating possible changes within the TNF-α system during psychological treatment for PTSD. Therefore, the present investigation suggests that clinical improvement following PTSD treatment might influence the production or release of TNF-α and sTNF-Rs.
Changes of TNF-α, sTNF-R p55 and sTNF-R p75 levels during psychological treatment could theoretically be due to a degree of recovery from PTSD or represent an effect or side effect of psychotherapy. However, our previous study did neither show any correlation between serum levels of TNF-α, sTNF-R p55 or sTNF-R p75 and the PDS scores in this patient sample (Himmerich et al. 2015) nor any statistically significant difference of TNF-α, sTNF-R p55 or sTNF-R p75 serum levels of soldiers with PTSD compared to those without PTSD (Himmerich et al. 2016 ). Consistent with these findings, in the present study we did not find any statistically significant association between the decrease in the PDS score and the changes in the parameters of the TNF-α system. Therefore, it seems unlikely that TNF-α, sTNF-R p55 or sTNF-R p75 levels changed as a result of an improvement of PTSD symptoms.
As animal studies have shown that TNF-α production increases during stressful events (Krügel et al. 2014) , one consideration may be that EMDR therapy, which includes imagination of a trauma, or being allocated to outpatient clinical management, instead of a perceived more favorable specific psychological treatment for PTSD (e.g. inpatient psychotherapy), could also lead to stress. Therefore, an increase of TNF-α production or release could be a side effect of psychotherapy or a result of patient disappointment.
From a psychopharmacological perspective, the increase of TNF-α production we observed is not surprising, since a number of effective psychopharmacological drugs, such as mirtazapine However, it may be that not psychotherapy itself, but rather behavioural consequences of psychotherapy or the behavioural changes associated with returning home after deployment have caused the observed alterations within the TNF-α system. Such changes could be due to nicotine or alcohol consumption, lifestyle, physical activity or diet. Unfortunately, we did not gather data on these factors longitudinally. Furthermore, the simple change of location and the consecutive adaptations within the immune system should also be taken into account when interpreting the present data.
The TNF-α parameters did not significantly differ between the inpatient psychotherapy group and the outpatient clinical management group. Therefore, inpatient psychotherapy (including Even though certain antidepressants are known to influence cytokine production (Kraus et al. 2002) , the use of antidepressants did not influence TNF-α, sTNF-R p55 and sTNF-R p75 levels in our sample. As the patients in our sample used different types of antidepressants, we could only compare patients taking antidepressants with those using no antidepressant medication. As some antidepressants, such as venlafaxine (Kraus et al. 2002) , may not influence TNF-α, sTNF-R p55 and sTNF-R p75 levels, our investigation is not suitable to study the influence of antidepressants on cytokine production specifically.
A further limitation of this study is the small sample size of 38 patients in total, with 21 in the inpatient psychotherapy group. However, psychopharmacological agents, such as the antidepressant mirtazapine, the mood stabilizers lithium and carbamazepine and the Another limitation of the present investigation is that sTNF-R p55 or sTNF-R p75 serum levels in these soldiers were not measured prior to deployment abroad. Such a longitudinal study design starting prior to deployment abroad would have enabled more specific conclusions about a possible connection between PTSD and parameters of the TNF-α system.
In addition, in the present study, we did not attempt to detect feigned PTSD or PTSD symptom exaggeration, in a standardized way, although measures for detecting malingering, such as specific scales of the Minnesota Multiphasic Personality Inventory-2 (MMPI-2), are available (Efendov et al. 2008 ). This issue might be specifically pertinent in soldiers because of eligibility for a state pension or other benefits if their PTSD is determined to be combatrelated and treatment-resistant. Therefore, one could question the initial PTSD diagnosis of these patients. However, the patients were assessed by an experienced military psychiatrist and obvious malingering would have obviated their inclusion in the study.
In conclusion, to our knowledge, we performed the first study investigating the effect of psychiatric therapy and specifically inpatient psychotherapy including EMDR on serum levels of TNF-α, sTNF-R p55 or sTNF-R p75 in PTSD patients. The specific inpatient psychotherapy but also non-specific outpatient clinical management treatment reduced PTSD symptoms as measured by the PDS score and altered TNF-α, sTNF-R p55 and sTNF-R p75 concentrations. It seems to be most likely that these changes are attributable to non-specific psychotherapeutic effect or side effects. From a methodological view, further confirmatory studies should incorporate a longitudinal design starting at the time before the deployment abroad, include a control group without any treatment, have a larger sample size and should try to detect feigned PTSD as well as PTSD symptom exaggeration. Table 1 : Mean and standard deviation (SD) of the descriptive variables age and body mass index (BMI) as well as the outcome parameters Posttraumatic Stress Diagnostic Scale (PDS) score and serum concentrations of tumor necrosis factor-α (TNF-α) and its soluble receptors (sTNF-R) p55 and p75 separately for both treatment groups at baseline and after treatment. Regarding the whole group, there was a significant increase in TNF-α serum concentration (p<.01), but a significant decrease of sTNF-R p55 (p<.05) and sTNF-R p75 (p<.05) levels during the treatment period. Significant group differences in TNF-α parameters (inpatient vs. outpatient therapy) were not detected. 
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